Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)

Analyst Ratings

Consensus Ratings for Marinus Pharmaceuticals (NASDAQ:MRNS) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $9.38 (383.25% upside)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Jefferies GroupReiterated RatingBuy$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2015Janney Montgomery ScottReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2014JMP SecuritiesInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/2/2016($0.41)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q416($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015($0.51)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015($0.51)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.47)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.39)$0.62ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3 14($0.50)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.40)($0.37)($0.39)
Q2 20162($0.40)($0.39)($0.40)
Q3 20162($0.39)($0.38)($0.39)
Q4 20162($0.39)($0.37)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateHeadline
07/23/16 09:10 AMEquity Roundup: Stock Performance Focus on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Press Telegraph
07/21/16 05:35 PMChecking in on Stock Volatility for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
07/21/16 08:08 AMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:08 AMInsiders Increasing Positions in: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Press Telegraph
07/19/16 05:24 PMShares Losing Ground in Session: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - TGP
07/19/16 09:51 AMStocks on the Move: Marinus Pharmaceuticals, Inc. (MRNS), Host Hotels & Resorts, Inc. (HST), The Coca-Cola ... - iStreetWire
07/19/16 09:51 AMAnalysts Watching Stocks: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) , Vertex Pharmaceuticals Incorporated ... - Street Updates
07/19/16 09:51 AMPerformance report of the company: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - News Oracle
07/19/16 09:51 AMBiotech Stocks Worth a Closer Look: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), Eleven Biotherapeutics, Inc ... - The Voice Registrar
07/18/16 10:34 AMMarinus Pharmaceuticals : Market Volatility Continues to Drive Investor Interest in These 4 Companies
07/17/16 04:44 PMMarinus Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/17/16 04:44 PMIncreased Volatility Noted on Shares of: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
07/17/16 04:44 PMAre Analysts Bullish Marinus Pharmaceuticals Inc (NASDAQ:MRNS) After Last Week? - Consumer Eagle
07/17/16 04:44 PMStock under consideration: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - News Oracle
07/15/16 09:50 AMStrong Sell Calls For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 0 - Investor Newswire
07/14/16 05:32 PMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 05:32 PMTrending Stocks In The News: Marinus Pharmaceuticals Inc (NASDAQ:MRNS), Himax Technologies, Inc. (ADR ... - NYSE Journal (press release)
07/14/16 05:32 PMNoteworthy Price Swings: EXACT Sciences Corporation (NASDAQ:EXAS) , Marinus Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/12/16 05:33 PMStock Volatility Focus for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
07/12/16 05:33 PMSession Volatility Review for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
07/12/16 05:33 PMShares Charging Upward in Session: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Telanagana Press
07/09/16 04:47 PMWere Analysts Bearish Marinus Pharmaceuticals Inc (NASDAQ:MRNS) This Week? - Engelwood Daily
07/08/16 05:22 PMIncreased Volatility on Shares of: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
07/08/16 08:11 AMMarinus Pharmaceuticals, Inc. Stock Momentum Hits Extreme Weakness - CML News
07/08/16 08:11 AMCan Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 08:11 AMIs $2.5 Within Reach For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)? - Investor Newswire
07/08/16 08:11 AMBroker Outlook For Marinus Pharmaceuticals, Inc. (MRNS) - Fiscal Standard
07/03/16 04:45 PMHow Many Marinus Pharmaceuticals Inc (NASDAQ:MRNS)'s Analysts Are Bullish? - Press Telegraph
07/03/16 04:45 PMMarinus Pharmaceuticals, Inc. (MRNS) Current Analyst Ratings - Fiscal Standard
06/30/16 08:10 AMMarinus Pharma (MRNS) Says Primary Endpoint Not Met in Ganaxolone Phase 2 Exploratory Study
06/29/16 05:10 PMWatching Stock Volatility for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
06/29/16 05:10 PMFrontline Matters in Notice- Marinus Pharmaceuticals (NASDAQ:MRNS), SolarCity (NASDAQ:SCTY), Iron Mountain ... - Seneca Globe
06/29/16 08:05 AMMarinus Pharmaceuticals, Inc. (MRNS) Updated Price Targets - FTSE News
06/28/16 05:09 PMCovering the Bases on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Where is the Stock Going? - Press Telegraph
06/28/16 05:09 PMCheck on Share Volatility: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
06/28/16 05:09 PMExpectations Surging for Marinus Pharma (MRNS) Trial Data; Regulus Therapeutics (RGLS) Crashes On FDA's ... - Galaxy Stocks (press release) (registration)
06/28/16 05:09 PMMarinus Pharma (MRNS) Says Primary Endpoint Not Met in Ganaxolone Phase 2 Exploratory Study - StreetInsider.com
06/28/16 10:08 AMMarinus (MRNS) Plans Conference Call to Reports Results From Phase 2 Study of Ganaxolone in Children with Fragile X
06/28/16 10:08 AMResults from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
06/28/16 10:08 AMExpectations Surging for Marinus Pharma (MRNS) Trial Data; Regulus Therapeutics (RGLS) Crashes On FDA’s Determination
06/27/16 05:10 PMMarinus Pharmaceuticals, Inc. (MRNS) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 03:21 PMMarinus Pharmaceuticals to Host Conference Call on Tuesday, June 28 - [at noodls] - RADNOR, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
06/25/16 04:52 PMShare Volatility Check for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Press Telegraph
06/25/16 04:52 PMAre Analysts Bullish Marinus Pharmaceuticals Inc (NASDAQ:MRNS) After Last Week? - Press Telegraph
06/23/16 05:46 PMStrong Sell Calls Recommendations For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 0 - Investor Newswire
06/23/16 07:58 AMMarinus Pharma (MRNS) Commences Dosing in Ganaxolone IV Phase 1 as SE Treatment
06/22/16 05:09 PMMarinus Pharma (MRNS) Commences Dosing in Ganaxolone IV Phase 1 as SE Treatment - StreetInsider.com
06/22/16 06:39 AMMarinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV - [at noodls] - RADNOR, Pa., June 22, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
06/20/16 04:46 AMAnalyst Views For The Week Ahead: Marinus Pharmaceuticals, Inc. (MRNS) - Fiscal Standard
06/19/16 09:15 AM6 Companies That Destroyed Shareholders Last Week -

Social

About Marinus Pharmaceuticals

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MRNS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.94
  • 50 Day Moving Average: $2.27
  • 200 Day Moving Average: $4.58
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $36.29M
  • Beta: 1.72
  • Current Year EPS Consensus Estimate: $-1.5 EPS
  • Next Year EPS Consensus Estimate: $-1.17 EPS
Additional Links:
Marinus Pharmaceuticals (NASDAQ:MRNS) Chart for Monday, July, 25, 2016